The Migraine and Pain Study GeneBank at Scripps Clinic Registry (MAPS)
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The objective of this study is to obtain blood or saliva samples to define genes for migraine and pain diseases.
| Condition |
|---|
|
Migraine Disease |
| Study Type: | Observational |
| Study Design: | Observational Model: Family-Based |
| Official Title: | The Migraine and Pain Study GeneBank at Scripps Clinic Registry (MAPS) |
Approximately 20 milliliters of blood will be dispensed as follows: 2 X 8.5 ml PAX DNA Tubes OR 2 mLs of Saliva may be collected from each patient in a provided container. Saliva will only be collected on those individuals who do not wish to undergo phlebotomy for blood collection.
| Enrollment: | 61 |
| Study Start Date: | January 2009 |
| Primary Completion Date: | September 2009 (Final data collection date for primary outcome measure) |
| Groups/Cohorts |
|---|
|
Migraine Disease
Patients 10 to 18 years of age with the diagnosis of Migraine disease and at least one of their biologic parents will be included in this study.
|
Detailed Description:
It is estimated that over one-third of the world's population suffers from persistent or recurrent pain. Migraine is highly heritable and the majority of juveniles who suffer from the disorder have a mother or father who also have the disease. The blood or saliva samples will go through DNA analysis and be sequenced for candidate genes or subjected to whole-genome sequencing. By creating a MAPS GeneBank from these patients' blood/saliva donations we will ultimately be able to define genes for migraine and pain diseases.
Eligibility| Ages Eligible for Study: | 10 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Non-Probability Sample |
Subjects will be recruited from the Migraine disease patient population at Scripps Clinic and around Southern California.
Inclusion Criteria:
- Family members (genetic duo or trio), consisting of an adolescent 10 to 18 years of age and at least one of their biologic parents willing to be participate in trial
- Adolescent and at least 1 biologic parent with Migraine diagnosis confirmed by Dr. Christy Jackson
- Is reliable, cooperative and willing to comply with all protocol-specified procedures and/or sub-study if consented
- Able to understand and grant informed consent
Exclusion Criteria:
- Patient has been previously enrolled in the MAP GeneBank at Scripps Clinic Registry
- Has a significant chronic medical condition (i.e.chronic meningitis or a secondary origin/cause of headache) which, in the investigator's option, may interfere with the patient's optimal participation in the study
- Treatment with any investigational agents or devices within 30 days preceding enrollment in the study
- Has undergone ECT within 90 days preceding enrollment in the study
Contacts and Locations| United States, California | |
| Scrippshealth | |
| La Jolla, California, United States, 92037 | |
| Principal Investigator: | Christy M Jackson, M.D. | Scrippshealth |
More Information
Additional Information:
No publications provided
| Responsible Party: | Eric Topol, MD, Director, Scripps Translational Science Institute, Scripps Translational Science Institute |
| ClinicalTrials.gov Identifier: | NCT01004835 History of Changes |
| Other Study ID Numbers: | HSC# 08-5099 |
| Study First Received: | October 29, 2009 |
| Last Updated: | January 20, 2012 |
| Health Authority: | United States: Institutional Review Board |
Keywords provided by Scripps Translational Science Institute:
|
migraine |
Additional relevant MeSH terms:
|
Migraine Disorders Headache Disorders, Primary Headache Disorders |
Brain Diseases Central Nervous System Diseases Nervous System Diseases |
ClinicalTrials.gov processed this record on May 16, 2013